New Mers-Cov Vaccine

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a new MERS-CoV vaccine based on mutant forms of the virus's receptor-binding domain (RBD) and spike protein. These mutants are engineered to have reduced binding to their natural host receptor (DPP4), which normally can mask critical regions of the viral spike and reduce vaccine-induced immune responses. By weakening this interaction through precise mutations, the vaccine aims to induce stronger and more effective neutralizing antibody production, leading to better protection against MERS-CoV infection.

Use CasesContent extracted from patent full text and abstract with AI.

• Pre-exposure vaccination of humans in regions at risk of MERS outbreaks.
• Vaccination of dromedary camels to prevent animal-to-human transmission.
• Post-exposure vaccination or therapeutic use in recent MERS-CoV infections to boost protective immunity.
• Development of improved diagnostic tools based on the mutant antigens for serological surveys.
• Potential application for rapid vaccine development against future MERS-CoV variants.

BenefitsContent extracted from patent full text and abstract with AI.

• Elicits stronger and more efficient neutralizing antibody responses compared to existing approaches.
• Overcomes the immune-masking effect caused by the natural receptor present in blood, especially in susceptible individuals.
• Can be tailored (using combinations of mutations) to provide broad coverage against different MERS-CoV variants.
• Relevant both as a preventive (prophylactic) and post-exposure (therapeutic) vaccine.
• Applicable to both humans and animals, supporting One Health approaches to MERS outbreak prevention.
• Protein/peptide/nucleic acid formats provide flexibility for different vaccine platforms (e.g., recombinant protein, mRNA, DNA).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a mutant receptor-binding domain (MERS-mRBD) of MERS-CoV (middle east respiratory syndrome coronavirus) or a fragment thereof and a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof.Furthermore, the present invention relates to a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof comprising the MERS-mRBD or the fragment thereof.Furthermore, the present invention relates to a polypeptide or protein comprising the MERS-mRBD or the fragment thereof or MERS-mSpike or the fragment thereof and a nucleic acid comprising a nucleotide sequence encoding for the MERS-mRBD or the fragment thereof or the MERS-mSpike or the fragment thereof.Furthermore, the present invention relates to a vaccine composition comprising one or more MERS-mRBDs or fragments thereof, one or more MERS -mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention.Furthermore, the present invention relates to the one or more MERS-mRBDs or fragments thereof, the one or more MERS-mSpikes, the one or more polypeptides or proteins, the one or more nucleic acids and/or the vaccine composition according to the present invention for use in the prevention and/or treatment of diseases caused by MERS-CoV in a subject.